Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2012

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Etanercept (Enbrel®) has been accepted for restricted use the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years. The restriction applies to disease severity and intolerance or inadequate response to other treatments.

Etanercept (Enbrel®) has also been accepted for restricted use in the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years. The restriction applies to use in specialist rheumatology services when there has been intolerance or inadequate response to methotrexate.

Insulin detemir (Levemir®) has been accepted for restricted use in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. The restriction applies to patients unable to achieve good glycaemic control with established insulins. The SMC note that this advice has been issued previously with a lower age limit of 6 years old.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2012' on Email Share 'SMC Update - May 2012' on Delicious Share 'SMC Update - May 2012' on Digg Share 'SMC Update - May 2012' on Facebook Share 'SMC Update - May 2012' on Google+ Share 'SMC Update - May 2012' on reddit Share 'SMC Update - May 2012' on StumbleUpon Share 'SMC Update - May 2012' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2012”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,318 spam comments.

atomic-wealth
fond-illness
summer